Azenta (AZTA) Stock Price, News & Analysis

Company Overview

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

Key Stats

• Today's Range: $26.42 to $27.37
• 50-Day Range: $25.03 to $37.15
• 52-Week Range: $23.91 to $63.58
• Volume: 254,037 shs
• Average Volume: 693,376 shs
• Market Capitalization: $1.23 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $50.67
• Consensus Rating: Moderate Buy

Azenta Stock Analysis - MarketRank™

Azenta scored higher than 78% of companies evaluated by MarketBeat, and ranked 202nd out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Azenta has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Azenta has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 73.58%

Earnings Growth

Earnings for Azenta are expected to grow by 73.58% in the coming year, from $0.53 to $0.92 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Azenta is -9.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Azenta is -9.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Azenta has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.92% of the float of Azenta has been sold short.

Short Interest Ratio / Days to Cover

Azenta has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in Azenta has recently decreased by 9.37%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Azenta does not currently pay a dividend.

Dividend Growth

Azenta does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Azenta will have a dividend payout ratio of 10.87% next year. This indicates that Azenta will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.92% of the float of Azenta has been sold short.

Short Interest Ratio / Days to Cover

Azenta has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in Azenta has recently decreased by 9.37%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 1.73

News Sentiment

Azenta has a news sentiment score of 1.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Azenta this week, compared to 5 articles on an average week.

MarketBeat Follows

Only 1 people have added Azenta to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Azenta insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.62% of the stock of Azenta is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

99.08% of the stock of Azenta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AZTA Stock Analysis - Frequently Asked Questions

How have AZTA shares performed this year?

Azenta's stock was trading at $50.00 on January 1st, 2025. Since then, AZTA stock has decreased by 45.9% and is now trading at $27.04.
View the best growth stocks for 2025 here.

How were Azenta's earnings last quarter?

Azenta, Inc. (NASDAQ:AZTA) posted its quarterly earnings results on Wednesday, May, 7th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by $0.04. Azenta's revenue for the quarter was up 5.1% on a year-over-year basis.
Read the conference call transcript.

Who are Azenta's major shareholders?

Top institutional shareholders of Azenta include Vanguard Group Inc. (9.68%), Kayne Anderson Rudnick Investment Management LLC (4.67%), Conestoga Capital Advisors LLC (4.19%) and GW&K Investment Management LLC (2.82%). Insiders that own company stock include John Marotta, David C Gray, Matthew Mcmanus, Herman Cueto, Olga Pirogova, William L Cornog and Violetta Hughes.
View institutional ownership trends.

How do I buy shares of Azenta?

Shares of AZTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Azenta own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Azenta investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 5/30/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Special industry machinery, not elsewhere classified
• Sub-Industry: Machinery
• Current Symbol: NASDAQ:AZTA
• CIK: 933974
• Web: www.brooks.com
• Phone: (978) 262-2400
• Fax: 978-262-2500
• Employees: 3,100
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $50.67
• High Stock Price Target: $60.00
• Low Stock Price Target: $40.00
• Potential Upside/Downside: +85.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.39)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 51.57
• P/E Growth: N/A
• Net Income: -$164.17 million
• Net Margins: -24.91%
• Pretax Margin: -25.77%
• Return on Equity: 1.25%
• Return on Assets: 1.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.18
• Quick Ratio: 3.78

Sales & Book Value

• Annual Sales: $669.17 million
• Price / Sales: 1.87
• Cash Flow: $2.78 per share
• Price / Cash Flow: 9.84
• Book Value: $36.16 per share
• Price / Book: 0.76

Miscellaneous

• Outstanding Shares: 45,780,000
• Free Float: 40,843,000
• Market Cap: $1.25 billion
• Optionable: Optionable
• Beta: 1.64